E. Newman

发表

Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

H. Lenz, P. LoRusso, S. Kummar, 2013, Clinical Cancer Research.

Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)

J. Riess, D. Gandara, P. Mack, 2021, Clinical lung cancer.

A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression

Y. Yen, J. Doroshow, D. Gandara, 2007, Cancer Chemotherapy and Pharmacology.

Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.

D. Priest, Y. Lu, K. Scanlon, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium – an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879

S. Groshen, D. Gandara, H. Lenz, 2021, Investigational New Drugs.

Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design.

S. Cherry, L. Nardo, J. Riess, 2020, Clinical lung cancer.

Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors

D. Gandara, H. Lenz, A. El-Khoueiry, 2014, British Journal of Cancer.

Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies

P. Kaesberg, P. Frankel, S. Forman, 2020, Leukemia & lymphoma.

Fluoropyrimidine biochemical modulation in colon cancer: pharmacology relevant in both the laboratory and the clinic.

J. Doroshow, E. Newman, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium.

J. Doroshow, L. Leong, S. Akman, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors

S. Groshen, J. Pinski, D. Gandara, 2021, Cancer Chemotherapy and Pharmacology.

Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial

S. Groshen, A. Yang, S. Kummar, 2017, Clinical Cancer Research.

A Phase 1 Trial Dose Escalation Study of Tipifarnib on a Week-On, Week-Off Schedule in Relapsed, Refractory or High-Risk Myeloid Leukemia

J. Wright, P. Frankel, S. Forman, 2011, Leukemia.

Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial

D. Gandara, H. Lenz, L. Appleman, 2019, Cancer Chemotherapy and Pharmacology.

A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients (NCI 10327): Rationale and Study Design

Ian R. Lanza, S. Cherry, L. Nardo, 2021 .

Selective killing of transformed cells by methotrexate with histidine deprivation or with alpha-amino alcohols.

D. Santi, D. Nierenberg, E. Newman, 1983, Cancer research.

Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors

Y. Yen, J. Doroshow, L. Leong, 1996, Cancer Chemotherapy and Pharmacology.

Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.

M. Milowsky, William Y. Kim, S. Srinivas, 2021, JAMA oncology.

Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion.

J. Doroshow, J. Straw, E. Newman, 1989, Cancer research.

Mechanisms of cross-resistance to methotrexate and 5-fluorouracil in an A2780 human ovarian carcinoma cell subline resistant to cisplatin.

Y. Lu, M. Kashani-Sabet, K. Scanlon, 1988, Biochemical pharmacology.

Untenable dosing: A common pitfall of modern DLT-targeting Phase I designs in oncology.

S. Groshen, P. Frankel, J. Longmate, 2020, Current problems in cancer.

Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial

J. Doroshow, D. Gandara, H. Lenz, 2015, Cancer Chemotherapy and Pharmacology.

Failure of pretreatment with intravenous folic acid to alter the cumulative hematologic toxicity of lometrexol.

S. Groshen, J. Doroshow, F. Muggia, 1996, Journal of the National Cancer Institute.

CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin

S. Kane, S. Forman, E. Newman, 2015, Molecular Cancer Therapeutics.

Oral and intravenous pharmacokinetics of 5-fluoro-2′-deoxycytidine and THU in cynomolgus monkeys and humans

J. Doroshow, S. Kummar, Myrtle A. Davis, 2015, Cancer Chemotherapy and Pharmacology.

Model of a Queuing Approach for Patient Accrual in Phase 1 Oncology Studies

S. Groshen, P. Frankel, S. Sampath, 2020, JAMA network open.

Eribulin in advanced urothelial cancer (AUC) patients (pts): A California Cancer Consortium trial—NCI/CTEP 7435.

S. Groshen, T. Dorff, W. Stadler, 2015 .

Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)--Final report: A California Cancer Consortium-led NCI/CTEP-sponsored trial.

S. Groshen, D. Gandara, T. Dorff, 2010 .

Phase I study of vorinostat, a histone deacetylase (HDAC) inhibitor, in combination with carboplatin (Cb) and paclitaxel (P) for patients with advanced solid malignancies (NCI #6922).

S. Ramalingam, A. Argiris, M. Egorin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.

Y. Yen, J. Doroshow, L. Leong, 1998, Cancer research.

A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study

Y. Yen, P. Frankel, Kenneth K. Chan, 2016, Leukemia & lymphoma.

Biochemical interactions between methotrexate and 1-β-d-arabinofuranosylcytosine in hematopoietic cells of children: a Pediatric Oncology Group study

R. Krance, Y. Ravindranath, A. Testi, 2004, Cancer Chemotherapy and Pharmacology.

A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial

J. Doroshow, D. Gandara, H. Lenz, 2005 .

Synthesis and antineoplastic activity of hydroquinone dialdehydes.

A. Sartorelli, E. Newman, A. Lin, 1980, Journal of medicinal chemistry.

Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies

P. Frankel, S. Forman, J. Tuscano, 2014 .

A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

S. Groshen, J. Dipersio, J. Tuscano, 2019, Clinical Cancer Research.

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

P. Frankel, J. Tuscano, C. Costello, 2019, Blood.

Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial

Y. Yen, J. Doroshow, D. Gandara, 2002, Cancer Chemotherapy and Pharmacology.

Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity.

S. Groshen, J. Doroshow, F. Muggia, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis

J. Doroshow, L. Leong, S. Akman, 2000, Cancer Chemotherapy and Pharmacology.

BCL2 Inhibition by Venetoclax: Targeting the Achilles' Heel of the Acute Myeloid Leukemia Stem Cell?

V. Pullarkat, E. Newman, 2016, Cancer discovery.

Preparation of (6R)-tetrahydrofolic acid and (6R)-5-formyltetrahydrofolic acid of high stereochemical purity.

R. Moran, E. Newman, J. Sato, 1986, Analytical biochemistry.

Microbiological analysis of 5-formyltetrahydrofolic acid and other folates using an automatic 96-well plate reader.

E. Newman, J. Tsai, 1986, Analytical biochemistry.

Simple and sensitive method for the quantitative analysis of lometrexol in plasma using high-performance liquid chromatography with electrochemical detection.

J. Doroshow, F. Muggia, T. Synold, 1996, Journal of chromatography. B, Biomedical applications.

Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies

J. Niland, Y. Yen, J. Doroshow, 2003, Cancer Chemotherapy and Pharmacology.

Size of the directing moiety at carbon 5 of cytosine and the activity of human DNA(cytosine-5) methyltransferase.

S. S. Smith, T. A. Hardy, D. Baker, 1987, Biochemical and biophysical research communications.

Sequential Oral Hydroxyurea and Intravenous Cytosine Arabinoside in Refractory Childhood Acute Leukemia: A Pediatric Oncology Group Phase 1 Study

Y. Ravindranath, B. Camitta, D. Mahoney, 2008, Journal of pediatric hematology/oncology.

Pharmacokinetics of Diastereoisomers of (6l?,5)-Folinic Acid (Leucovorin) in Humans during Constant High-Dose Intravenous Infusion1

J. Doroshow, J. Straw, E. Newman, 2006 .

Phase I study of phosphonacetyl-l-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer

R. Ozols, P. O'dwyer, G. Hudes, 2004, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics and toxicity of continuous infusion (6S)-folinic acid and bolus 5-fluorouracil in patients with advanced cancer.

J. Doroshow, L. Leong, S. Akman, 1992, Cancer research.

A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine, administered with tetrahydrouridine

J. Doroshow, H. Lenz, A. El-Khoueiry, 2015, Cancer Chemotherapy and Pharmacology.

Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU)

James H. Doroshow, Merrill J. Egorin, J. Doroshow, 2008, Cancer Chemotherapy and Pharmacology.

Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

S. Steinberg, L. Rubinstein, J. Nieva, 2020, Cancer Chemotherapy and Pharmacology.

Metabolism and mechanism of action of 5-fluorodeoxycytidine.

D. Santi, E. Newman, 1982, Proceedings of the National Academy of Sciences of the United States of America.

A pilot study of intermediate‐dose methotrexate and cytosine arabinoside, “Spread‐out” or “Up‐front,” in continuation therapy for childhood non‐T, non‐B acute lymphoblastic leukemia a pediatric oncology group study

J. Shuster, R. Krance, Y. Ravindranath, 1991 .

Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study

Y. Yen, J. Doroshow, D. Gandara, 2009, Cancer Chemotherapy and Pharmacology.

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083

A. Chen, D. Gandara, M. Goetz, 2017, Clinical Cancer Research.

A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

Larry Rubinstein, James H Doroshow, L. Rubinstein, 2012, Clinical Cancer Research.

Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).

S. Groshen, T. Dorff, L. Doyle, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics of high‐dose etoposide

J. Doroshow, S. Forman, Edward M Newman, 1988, Clinical pharmacology and therapeutics.

Pharmacology and phase I trial of high-dose oral leucovorin plus 5-fluorouracil in children with refractory cancer: a report from the Children's Cancer Study Group.

G. Reaman, M. Krailo, J. Finklestein, 1991, Cancer research.

A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study

K. Foon, P. Frankel, J. Tuscano, 2014, Leukemia & lymphoma.

Phase I trial of continuous infusion 5-aza-2′-deoxycytidine

P. Laird, L. Leong, S. Baker, 2003, Cancer Chemotherapy and Pharmacology.

A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study

Y. Yen, D. Gandara, S. Ramalingam, 2012, Cancer Chemotherapy and Pharmacology.

A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors

S. Groshen, H. Lenz, S. Iqbal, 2013, Cancer Chemotherapy and Pharmacology.

A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study

D. Gandara, P. Frankel, J. Tuscano, 2018, British journal of haematology.

Pharmacokinetics of leucovorin (D,L-5-formyltetrahydrofolate) after intravenous injection and constant intravenous infusion.

J. Doroshow, J. Straw, E. Newman, 1987, NCI monographs : a publication of the National Cancer Institute.

Mechanisms for cisplatin-FUra synergism and cisplatin resistance in human ovarian carcinoma cells both in vitro and in vivo.

Y. Lu, M. Kashani-Sabet, K. Scanlon, 1988, Advances in experimental medicine and biology.

Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: Comparison of real‐time reverse transcription‐PCR vs. Relative quantification reverse transcription‐PCR utilizing DNA sequencer analysis of PCR products

Y. Yen, J. Doroshow, D. Gandara, 2003, Journal of clinical laboratory analysis.

Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

A. Nademanee, D. Gandara, P. Frankel, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycyticine (FdCyd) & its metabolites 5-fluoro-2'-deoxyuridine (FdUrd), 5-fluorouracil (FU), 5-fluorouridine (FUrd), & 5-fluorocytosine (FC) in plasma of patients treated with FdCyd.

J. Doroshow, H. Lenz, M. Egorin, 2006, Journal of Clinical Oncology.

Continuous Intratumoral Infusion of Methotrexate for Recurrent Glioblastoma: A Pilot Study

R. Harbaugh, D. Nierenberg, J. Fratkin, 1991 .

Continuous intratumoral infusion of methotrexate for recurrent glioblastoma: a pilot study.

R. Harbaugh, D. Nierenberg, J. Fratkin, 1991, Neurosurgery.

Fluorouracil and leucovorin in advanced breast cancer.

J. Doroshow, L. Leong, S. Akman, 1993, Advances in experimental medicine and biology.

A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors

S. Groshen, K. Kelly, D. Gandara, 2018, Cancer Chemotherapy and Pharmacology.

Mechanism of human methyl-directed DNA methyltransferase and the fidelity of cytosine methylation.

S. S. Smith, Steven S. Smith, B. Kaplan, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Biochemical and cytotoxic actions of 3,6-dihydroxy-4,5-dimethylphthalaldehyde in sarcoma 180 cells.

A. Sartorelli, E. Newman, 1981, Cancer research.

Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: An ETCTN California cancer consortium phase I study.

S. Groshen, C. Paweletz, P. Jänne, 2019, Journal of Clinical Oncology.

Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma

W. Chan, Xiwei Wu, L. Kwak, 2019, Clinical Cancer Research.

Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea

J. Doroshow, L. Leong, S. Akman, 2004, Cancer Chemotherapy and Pharmacology.

Abstract A106: Investigation of 5-fluorodeoxycytidine with tetrahydrouracil as a demethylation regimen in solid tumors.

J. Doroshow, R. Parchment, S. Kummar, 2011 .

A phase I study of ABT-888 (A) in combination with metronomic cyclophosphamide (C) in adults with refractory solid tumors and lymphomas.

J. Doroshow, A. Chen, D. Gandara, 2010 .

Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.

S. Groshen, C. Paweletz, H. Wakelee, 2022, Journal of Clinical Oncology.

J. Shuster, R. Krance, Y. Ravindranath, 1991, Cancer.

Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance: A California Cancer Consortium Phase II Trial (NCI 9303).

D. Gandara, P. Mack, S. Gadgeel, 2015 .